FenoMark Diagnostics AB received Breakthrough Device Designation from the FDA for its blood test.
Public source
Publisher name
Public post
The FDA gave Freenome's blood test Breakthrough Device Designation on 12 August. Early data seems promising, and the goal is to improve CT screening rates of at-risk pat…
Company
FenoMark Diagnostics AB
The best cancer treatment for all with robust, reliable and data rich proteomics on routinely biobanked FFPE tissue
- Industry
- Biotechnology Research
- Location
- Solna, SE
- Company size
- 2–10 employees
About FenoMark Diagnostics AB
Dedicated to improving cancer care by developing better diagnostic assays for therapy selection.
See moreLatest activity
Latest activity from FenoMark Diagnostics AB
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Guardant Health
Guardant Health announced that the Guardant360 CDx assay was approved by the FDA as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with camizestrant.
Legal & Regulatory
MERIT CRO
MERIT CRO received Breakthrough Therapy and Fast Track designations from the FDA for 68Ga-NYM096, a PET imaging agent for clear cell renal cell carcinoma showing 100% sensitivity and 96% accuracy in differentiating clear cell renal cell carcinoma from non-ccRCC lesions without invasive tissue sampling.
Legal & Regulatory
Upfront Diagnostics
Upfront Diagnostics received CE mark certification for LVOne.
Legal & Regulatory
OpenOnco
OpenOnco notes that the FDA advisory committee reviewed Galleri, the first MCED test to reach one, on September 23.
Legal & Regulatory
University of Hawai'i Cancer Center